Clinical trials: Recurring Major Depressive Disorder
Major Depressive Disorder
Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants.
- Trial name
- NCT04181567
- Testing
- electroconvulsive therapy, agomelatine
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Major Depression, Diabetes
Preventing Depression Recurrence in Diabetes
To study the effectiveness of sertraline (Zoloft) in treating depression in adults with diabetes. The study will also determine whether depressed diabetic patients who have successfully responded to sertraline (Zoloft) are more…
- Trial name
- NCT00374426
- Testing
- sertraline
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recurrent Major Depressive Disorder With Atypical Features
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression.
- Trial name
- NCT00585585
- Testing
- betahistine dihydrochloride
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an…
- Trial name
- NCT00878748
- Testing
- Effexor XR, Effexor XR discontinue
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
- Trial name
- NCT05733546
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 102 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Bipolar Disorder
Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery
Adults with serious mental illness (SMI) are disproportionately affected by medical comorbidity, earlier onset of disease, and 10 to 25 years reduced life expectancy compared to the general population.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Recurrent, Obesity
- Trial name
- NCT04481737
- Testing
- Peer-delivered and Technology Support Integrated Illness Management and Recovery, Peer support
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe
Practical Application of Accelerated iTBS for MDD
The goal of this observational study is to evaluate the feasibility and efficacy of accelerated iTBS in adults diagnosed with Major Depressive Disorder.
- Conditions
- Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe, Major Depressive Disorder, Recurrent, Moderate
- Trial name
- NCT06113575
- Testing
- NeuroStar TMS
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sonder Behavioral Health and Wellness
Healthy, Major Depressive Disorder (MDD)
Neurobiological and Genomic Predictors of Relapse in Depression
The goal of this observational study is to test whether the discontinuation of antidepressant medications for patients with depression can be decided after the normalization of biological parameters.
- Trial name
- MDD (NCT07328373)
- Testing
- Antidepressant Medications
- Where
- Turkey (Türkiye)
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Mehmet Kemal Arikan
Recurrent Major Depression
Neural Effects of Wellness Classes in Women With Vulnerability to Depression ("The Women's Wellness Study")
The primary objective of the study is to examine the efficacy of mindfulness based cognitive therapy (MBCT) on the prevention of relapse in women with a history of depression.
- Trial name
- WWS (NCT04106375)
- Testing
- Online mindfulness based cognitive therapy intervention
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Boulder
Late-life Depression, Major Depressive Disorder
Cognitive Behavioural Therapy for the Treatment of Late Life Depression
This study addresses the unmet medical problem of insufficient treatment of late life depression (LLD). Compared with depression in early adulthood, treatment options of LLD are limited.
- Conditions
- Late-life Depression, Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent
- Trial name
- CBTlate (NCT03735576)
- Testing
- Psychotherapy, Questionnaires, Magnetic Resonance Imaging
- Where
- 7 sites in Germany
- Volunteers
- 250 people
- Sponsor
- University of Cologne
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorders
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive…
- Trial name
- NCT00825019
- Testing
- amibegron (SR58611A), paroxetine
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- Sanofi
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Treatment Resistant Depression, MDD
Psilocybin rTMS for Treatment Resistant Depression
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with…
- Conditions
- Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression
- Trial name
- PSILOBSD (NCT06132178)
- Testing
- Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Major Depressive Disorder
Wellness Monitoring for Major Depressive Disorder
The Wellness Monitoring for Major Depressive Disorder (MDD) study is a prospective, longitudinal, observational study aimed at identifying biomarkers of relapse in MDD.
- Trial name
- CBN-Well (NCT02934334)
- Testing
- Observational
- Where
- 5 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Sidney Kennedy
Schizophrenia Disorders, Personality Disorders
Recovery in Telling Life Stories
This project tests the Recovery In Telling Life Stories (RETELL) intervention, aimed at supporting personal recovery in people with severe mental illness (SMI).
- Conditions
- Schizophrenia Disorders, Personality Disorders, Obsessive - Compulsive Disorder, Anxiety Disorders
- Trial name
- RETELL (NCT07082777)
- Testing
- Narrative therapy
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Depression - Major Depressive Disorder, Anxiety
Impact of Behavioral Activation on Depression and Quality of Life in Patients with Colon Cancer
The purpose of this randomized clinical trial is to study anxiety and depression symptoms at diagnosis in patients with colon cancer. Previous studies have shown that so-called.
- Conditions
- Depression - Major Depressive Disorder, Anxiety, Colon Cancer
- Trial name
- BAdepCa (NCT06745700)
- Testing
- Brief Behavioural Activation, Care as usual
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Region Västmanland
Depression
Comparing Various Treatments for Achieving and Maintaining Remission of Depression
This study will evaluate the effectiveness of five combinations of drug therapy and psychotherapy in maintaining remission of depression symptoms in people with recurrent major depression.
- Trial name
- NCT00227955
- Testing
- Imipramine, Interpersonal Psychotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)
The purpose of the study is to explore the Tolerability and Safety of the H-Coil deep Transcranial Magnetic Stimulation (TMS) in combination with Serotonin Selective Reuptake Inhibitor (SSRI) for Subjects with Major Depression…
- Trial name
- NCT01361815
- Testing
- H-Coil Deep TMS in combination with SSRIs
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 75 people
- Sponsor
- Brainsway